Emphasizing the role of good statistical practices (GSP) in drug research and formulation, this book outlines important statistics applications for each stage of pharmaceutical development to ensure the valid design, analysis, and assessment of drug products under investigation and establish the saf
Drug Development for Rare Diseases (Chapman & Hall/CRC Biostatistics Series)
β Scribed by Bo Yang (editor), Yang Song (editor), Yijie Zhou (editor)
- Tongue
- English
- Leaves
- 232
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
A disease is defined as rare if the prevalence is fewer than 200,000 in the United States. It is estimated that there are more than 7,000 rare diseases, which collectively affect 30 million Americans or 10% of the US population. This diverse and complex disease area poses challenges for patients, caregivers, regulators, drug developers, and other stakeholders. This book is proposed
to give an overview of the common issues facing rare disease drug developers, summarize challenges specific to clinical development in small populations, discuss drug development strategies in the evolving regulatory environment, explain generation and utilization of different data and evidence
inside and beyond clinical trials, and use recent examples to demonstrate these challenges and the development strategies that respond to the challenges.
Key Features:
β’ Rare disease.
β’ Drug development.
β’ Innovative clinical trial design.
β’ Regulatory approval.
β’ Real-world evidence.
π SIMILAR VOLUMES
Being that pharmacokinetics (PK) is the study of how the body handles various substances, it is not surprising that PK plays an important role in the early development of new drugs. However, the clinical research community widely believes that mathematics in some way blurs the true meaning of PK. De
<p><span>Cancer is a dreaded disease. One in two people will be diagnosed with cancer within their lifetime. </span><span>Medical Statistics for Cancer Studies</span><span> shows how cancer data can be analysed in a variety of ways, covering cancer clinical trial data, epidemiological data, biologic
<p><span>A health disparity refers to a higher burden of illness, injury, disability, or mortality experienced by one group relative to others attributable to multiple factors including socioeconomic status, environmental factors, insufficient access to health care, individual risk factors, and beha
Now viewed as its own scientific discipline, clinical trial methodology encompasses the methods required for the protection of participants in a clinical trial and the methods necessary to provide a valid inference about the objective of the trial. Drawing from the authorsβ courses on the subject as
<p>Survival data analysis is a very broad field of statistics, encompassing a large variety of methods used in a wide range of applications, and in particular in medical research. During the last twenty years, several extensions of "classical" survival models have been developed to address particula